Neuron Bio to extend its patent application for the Alzheimer’s diagnostic aid test to 148 PCT member states

Figure. Member states of Patent Cooperation Treaty (PCT) are shown in blue.

On 10 March 2016 Neuron Bio (NEU.MC) has extended its European patent application for the Alzheimer’s diagnostic aid test AlzTest®, to 148 contracting states of the Patent Cooperation Treaty (PCT) with file number PCT/EP2016/055090.

The content of the international patent application that protects the test AlzTest® and the international search report shall be publicly available within six months, in line with the normal time limits of this international extension procedure. The step from the European application to the international application authorizes Neuron Bio to protect its invention globally.

AlzTest® is a test to aid in the diagnosis of Alzheimer’s disease, developed by Neuron Bio that uses a mathematical algorithm based on the analysis of 5 blood markers and 3 sociodemographic markers. The method has been developed by the company in collaboration with researchers and neurologists of the hospital Virgen de las Nieves and Clínico in Granada and of the hospital Ramón y Cajal and La Paz in Madrid.

Thus, Neuron Bio continues developing the marketing process of the AlzTest®, being this one more step in the implementation of the business plan presented recently by the company.